Sulfone-substituted anilinopyrimidine derivatives as CDK inhibitors, the production thereof, and use as a medicine
View Patent ↗The invention relates to sulphone-substituted anilinopyrimidine derivatives of the formula (I), to its preparation processes, and to its use as medicament for treating various diseases.
1. Compounds of formula (I),
in which
R 1 is C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl or phenyl, in each case optionally substituted one or more times, identically or differently, with hydroxy, —NR 3 R 4 , cyano, halogen, —CF 3 , C 1 -C 6 -alkoxy, —OCF 3 or C 1 -C 6 -alkyl,
R 2 is C 1 -C 10 -alkyl, C 3 -C 10 -alkenyl, C 3 -C 10 -alkynyl or C 3 -C 7 -cycloalkyl,
in each case optionally substituted one or more times, identically or differently, with
a) halogen, hydroxy, —NR 3 R 4 , cyano, —CF 3 , or —OCF 3 , or
b) C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, —O—CH 2 -phenyl, or C n -alkoxycarbonyl,
in each case optionally substituted themselves one or more times, identically or differently, with halogen, hydroxy, C 1 -C 6 -alkyl, C 1 -C 6 -alkoxy, —NR 3 R 4 , —CF 3 or —OCF 3 ,
R 3 and R 4 independently of one another, are hydrogen, C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 8 -cycloalkyl, phenyl, heterocyclyl having 3 to 8 ring atoms, or monocyclic heteroaryl, optionally substituted one or more times, identically or differently, with hydroxy, —NR 5 R 6 , cyano, halogen, —CF 3 , C 1 -C 6 -alkoxy or OCF 3 ,
or
R 3 and R 4 together with the nitrogen atom, form a 5- to 7-membered ring which, optionally, in addition to the nitrogen atom, contains one or two further heteroatoms and which may be substituted one or more times, identically or differently, with hydroxy, —NR 5 R 6 , cyano, halogen, —CF 3 , C 1 -C 6 -alkoxy or —OCF 3 , and
R 5 and R 6 independently of one another, are hydrogen or C 1 -C 6 -alkyl, which is optionally substituted one or more times, identically or differently, with hydroxy, cyano, halogen, —CF 3 , C 1 -C 6 -alkoxy or —OCF 3 ,
and salts, diastereomers and enantiomers thereof.
2. Compounds according to claim 1 ,
where
R 1 is C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 7 -cycloalkyl or phenyl, in each case optionally substituted one or more times, identically or differently, with hydroxy, cyano, halogen, —CF 3 , C 1 -C 6 -alkoxy, —OCF 3 or C 1 -C 6 -alkyl,
and salts, diastereomers and enantiomers thereof.
3. Compounds according to claim 1 ,
where
R 2 is C 1 -C 10 -alkyl, C 3 -C 10 -alkenyl, C 3 -C 10 -alkynyl radical or a C 3 -C 7 -cycloalkyl ring,
in each case optionally substituted one or more times, identically or differently, with halogen, hydroxy, cyano, —CF 3 , —OCF 3 , or C 1 -C 6 -alkoxy, C 1 -C 6 -alkyl, in each case optionally substituted themselves one or more times, identically or differently, with halogen or hydroxy,
and salts, diastereomers and enantiomers thereof.
4. Compounds according to claim 1 ,
wherein
R 1 is C 1 -C 6 -alkyl, C 2 -C 6 -alkenyl, C 3 -C 7 -cycloalkyl or phenyl, in each case optionally substituted one or more times, identically or differently, with hydroxy, cyano, halogen or C 1 -C 6 -alkyl,
and salts, diastereomers and enantiomers thereof.
5. Compounds according to claim 1 ,
where
R 2 is C 2 -C 6 -alkyl, C 3 -C 6 -alkenyl, C 3 -C 6 -alkynyl or C 3 -C 7 -cycloalkyl, which is optionally substituted one or more times with hydroxy, halogen, —CF 3 or C 1 -C 3 -alkoxy,
and salts, diastereomers and enantiomers thereof.
6. Compounds according to claim 1 ,
where
R 2 has the formula (I −R 2 ),
in which
R a is methyl, ethyl, propyl or isopropyl, and
R b and R c independently of one another, are hydrogen, methyl or ethyl,
and salts, diastereomers and enantiomers thereof.
7. Compounds according to claim 6 ,
where
R a and R b are methyl and R c is hydrogen or methyl, and salts, diastereomers and enantiomers thereof.
8. Compounds of formula (Ia)
in which
R 1 is methyl or cyclopropyl,
R a and R b are methyl group, and
R c is hydrogen or methyl,
and salts, diastereomers and enantiomers thereof.
9. Process for the preparation of the compounds according to claim 1 , comprising at least one of the steps
a1) functionalization of the 4-position of 2,4-dichloro-5-iodopyrimidine (1)
by reaction with an alcohol of formula (2)
to form an intermediate of formula (3),
and subsequent reaction of the intermediate of formula (3) to form the 5-CF 3 intermediate (4)
or alternatively
a2) direct reaction of 2,4-dichloro-5-trimethylpyrimidine (5)
and an alcohol of formula (2)
to form the 5-CF 3 intermediate (4),
b) oxidation of a thioether of formula (7)
to give the sulphone of formula (8),
c) reduction of the compound of formula (8)
to a compound of the formula (9),
d) coupling of the compound of formula (4)
and the compound of formula (9)
to yield a compound of formula (1)
where the substituents R 1 and R 2 have the meanings given in claim 1 .
10. Compounds according to claim 1 for use as medicament.
11. A method for producing a medicament for the treatment of cancer which comprises formulating a compound of claim 1 into a pharmaceutically acceptable composition.
12. Pharmaceutical formulation comprising a compound according to claim 1 and a pharmaceutically acceptable excipient.